Biogen reported 2% year-on-year revenue growth and 31% non-GAAP EPS growth. Management also updated full-year EPS guidance to $14.25 to $15.25, reflecting $1.00 per share of acquired in-process research and development expense. Shares rose 6% April 30 from the previous day's close.
Biogen remains a significant player in the $20 billion global MS market with Vumerity, Avonex, Plegridy, Tysabri, and Tecfidera, although its portfolio has been declining due to competitive pressures from newer drugs and loss of exclusivity events.
Biogen's MS portfolio is under pressure from newer branded drugs as well as generic and biosimilar versions of its older therapies.
|
Metric
|
BIIB
|
SNY
|
|---|---|---|
Price/Earnings (Normalized) | 12.33 | 10.69 |
Price/Book Value | 1.55 | 1.29 |
Price/Sales | 2.90 | 2.00 |
Price/Cash Flow | 8.37 | 9.15 |
|
Metric
|
BIIB
|
SNY
|
|---|---|---|
Quick Ratio | 2.03 | 0.20 |
Current Ratio | 3.06 | 1.01 |
Interest Coverage | 6.39 | 11.82 |
|
Metric
|
BIIB
|
SNY
|
|---|---|---|
Return on Assets (Normalized) | 8.07% | 7.49% |
Return on Equity (Normalized) | 13.00% | 13.70% |
Return on Invested Capital (Normalized) | 9.98% | 10.47% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Jnvnkfjz | Gvh | $1T | |||
| Johnson & Johnson
JNJ
| Djgxxgnht | Rtgjy | $560B | |||
| AbbVie Inc
ABBV
| Xpfkywrlm | Cskj | $401B | |||
| Roche Holding AG ADR
RHHBY
| Zfynrdqgh | Pnyp | $330B | |||
| Merck & Co Inc
MRK
| Mnhjqjcrm | Zxtw | $298B | |||
| AstraZeneca PLC
AZN
| Bwxfhswh | Pykm | $288B | |||
| Novartis AG ADR
NVS
| Wbyrzlsxgn | Vypf | $285B | |||
| Novo Nordisk AS ADR
NVO
| Gsqmmmgc | Mswx | $195B | |||
| Amgen Inc
AMGN
| Vnlrmrtbt | Czxm | $189B | |||
| Gilead Sciences Inc
GILD
| Jmjwwfvw | Sjp | $160B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/0f2146bc-8a38-4a78-8fb8-fe1b37fb7287.jpg)
United States